Medical

Magazine articles on health care providers, pharmaceutical companies, and medical technology.

Old Articles: <Older 1361-1370 Newer>

The Motley Fool August 13, 2004 Charly Travers	Smaller Market for Insomnia Drugs A market research report shows insurers might not cover some drugs for this condition.
The Motley Fool August 13, 2004 Rich Duprey	Cima's Breakup Mess The pharmaceutical company seeks to recoup its fees plus damages from a former suitor.
BusinessWeek August 30, 2004 Gene G. Marcial	PSS Is Really Delivering The Goods When David Smith took the CEO job at PSS World Medical in 2000, sales stood at $160 million. They've since rocketed to $1.35 billion. No wonder industry giants are eyeballing the company: They hope Smith will sell.
The Motley Fool August 11, 2004 Charly Travers	Utah Medical Slapped by the FDA In this suit, the FDA is seeking to bar the company from manufacturing and distributing medical devices until it complies with the FDA's Quality System regulation (QSR). This event rocked the stock, sending it down nearly 33% for the day.
The Motley Fool August 11, 2004 Rich Smith	Natus Medical's Prognosis Infant-care specialist Natus Medical promises a profit next quarter.
The Motley Fool August 10, 2004 Brian Gorman	Biotech Cost Control Will the high cost of therapies slow sales in the sector? Investors can avoid problems by paying close attention to companies' pipelines and reimbursement trends.
BusinessWeek August 16, 2004 Engardio et al.	Outsourcing: Fortress India? U.S. and European companies that are outsourcing work overseas are under growing pressure from regulators and legislators to guarantee the privacy of their customers' financial and health-care data.
The Motley Fool August 6, 2004 Jeff Hwang	Stent Recall Stings Medical device maker Boston Scientific's recall has happened at a crucial time. Will the company lose its market share?
The Motley Fool August 6, 2004 Roger Nusbaum	Diagnosing WebMD's Health WebMD provides a useful website, but its investment potential isn't clear.
The Motley Fool August 6, 2004 Zeke Ashton	Are Biotechs Worth the Risk? Even when their drugs are doing well, companies in this industry don't necessarily yield big rewards for investors.
<Older 1361-1370 Newer> Return to current articles.